Five things for pharma marketers to know: Friday, May 25, 2018

Share this content:

AstraZeneca got a big win in late-stage study results for lung cancer drug Imfinzi. The drug's success could prove to investors that new treatments could finally provide the financial turnaround that AstraZeneca needs after Crestor went generic. (Endpoints News)

Johnson & Johnson has lost another talc lawsuit, this time in California. The pharma company must pay $25.7 million in damages to a woman who said J&J baby powder exposed her to asbestos and caused her mesothelioma. In April, a New Jersey court ordered the company to pay $117 million in a similar case. (CNBC)

Cancer drugs account for about 80% of drug sales worldwide, according to a new report from IQVIA. In the U.S., spending on oncology medicines has doubled since 2012, reaching just under $50 billion last year. (BioPharma Dive)

FDA has approved BioMarin Pharmaceutical's rare disease drug, Palynziq. The drug treats phenylketonuria, a rare metabolic disorder. Analysts said the approval is “an important vote of confidence” for BioMarin's future with new drugs as shares rose 3%. (Reuters)

Implementing Right to Try legislation could be FDA Commissioner Scott Gottlieb's biggest challenge yet, given the complex nature of the bill. Gottlieb tweeted this week that he wants to implement the bill “in a way that achieves Congress' intent to promote access and protect patients and build on FDA's longstanding commitment to these important goals.” (NPR)

Share this content:
Scroll down to see the next article